The VAPrapid2 trial conducted among non-COVID-19 patients at VAP suspicion found no impact on antibiotic consumption of therapy guided by BAL IL-1β and IL-8 measurement compared to routine management [11]. The gene discussed is CXCL8; the disease is COVID-19.